ValnevaValneva SE, the French specialty‑vaccine developer, has completed an €84m reserved offering, adding a useful cash buffer just as the group enters a high‑risk window for its Lyme disease and shigellosis‑vaccine candidates.
Tag Archive for: Valneva
WLan HoldingFairJourney Biologics (Porto, PT) has appointed Dr Werner Lanthaler, long-standing Evotec CEO, as Chief Executive Officer. Founder António Parada will focus on innovation strategy on the Supervisory Board.
Armed Forces Institute of Pathology, AFIPFrench-Austrian vaccine maker Valneva SE has secured exclusive worldwide rights to commercialise LimmaTech Biologics AG’s S4V Shigella vaccine that will be tested in two Phase II trials starting in H2/2024.
Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
French vaccine maker Valneva SE will double the amount of a US$100m debt financing granted by Deerfield Management Company and OrbiMed.
Valneva has appointed Dipal Patel as new Chief Commercial Officer and Management Board member.